VRAY - ViewRay, Inc.

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
7.72
0.00 (0.00%)
At close: 4:00PM EDT

7.72 0.00 (0.00%)
After hours: 4:47PM EDT

Stock chart is not supported by your current browser
Previous Close7.72
Open7.71
Bid6.15 x 1000
Ask7.74 x 100
Day's Range7.53 - 7.85
52 Week Range4.40 - 10.64
Volume374,596
Avg. Volume581,430
Market Cap553.864M
Beta0.91
PE Ratio (TTM)N/A
EPS (TTM)-1.24
Earnings DateNov 13, 2017 - Nov 17, 2017
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est10.92
Trade prices are not sourced from all markets
  • MarketWatch5 days ago

    Harry Boxer’s biotech-stock breakouts to watch

    In focus: uniQure, Supernus Pharmaceuticals and ViewRay.

  • PR Newswire5 days ago

    VU University Medical Center in Amsterdam Delivers First Ever Linear Accelerator-Based On-Table Adaptive MR Image-Guided Radiotherapy Treatment on ViewRay MRIdian® Linac

    CLEVELAND, April 19, 2018  /PRNewswire/ -- ViewRay, Inc. (VRAY) announced today that VU University Medical Center (VUmc) in Amsterdam has begun patient treatments using the Company's next generation system, MRIdian Linac. This is the first ever linear accelerator-based MR image-guided radiotherapy session delivered using on-table adaptation to correct for anatomical movements that occur each day throughout a patient's course of therapy. In May 2016, VUmc began on-table adaptive MR-image guided treatments with the first generation MRIdian system, which VUmc intends to upgrade to linac technology later in 2018.

  • ViewRay Unveils New Soft Tissue Visualization Technologies to Further Advance MR Image-Guided Radiotherapy
    PR Newswire6 days ago

    ViewRay Unveils New Soft Tissue Visualization Technologies to Further Advance MR Image-Guided Radiotherapy

    Designed to improve tumor and soft tissue visualization, these enhancements to MRIdian's SmartVISION™ MR image guidance are expected to further improve the precision by which radiation is delivered to treat cancer. MRIdian's SmartVISION first pioneered MR image-guided radiotherapy by allowing oncologists to visualize tumors and surrounding organs with diagnostic-quality MR imaging during treatment delivery. Also being developed for MRIdian's SmartVISION, Diffusion Weighted Imaging (DWI) may be used to distinguish between tumor and normal tissues and potentially assess and predict tumor response to radiation therapy.

  • PR Newswire28 days ago

    ViewRay Surpasses 50th Order for MRIdian® System for Precision Cancer Treatment

    Milestone Demonstrates Rapid Adoption of Next-Generation MR-Image Guided Radiation Therapy CLEVELAND , March 27, 2018 /PRNewswire/ -- ViewRay, Inc. (Nasdaq: VRAY) announced that the company surpassed its ...

  • Zacks Small Cap Researchlast month

    VRAY: 2018 Could Be Pivotal For ViewRay

    By Anita Dushyanth, PhD NASDAQ:VRAY Financial Update: On March 12, 2018 ViewRay, Inc. (NASDAQ:VRAY) announced financial results for the fourth quarter and fiscal year 2017.   In just the first year after ...

  • PR Newswirelast month

    Nearly 200 Oncology Experts Gather to Discuss Advanced Applications of MR Image-Guided Radiotherapy

    Educational Event Featured Presentations from Five MRIdian® Users Highlighting MR Image-guided Radiation Therapy Clinical Experience and Best Practices CLEVELAND , March 16, 2018 /PRNewswire/ -- Experts ...

  • PR Newswirelast month

    ViewRay's MRIdian MR Image-Guided Radiotherapy Linac Receives Japanese Regulatory Approval (Shonin)

    CLEVELAND, March 15, 2018 /PRNewswire/ -- ViewRay, Inc. (VRAY) announced today that the company received Shonin approval from the Japanese Ministry of Health, Labor and Welfare (MHLW) to market the MRIdian Linac System, the company's next-generation MRIdian System, featuring linear accelerator (Linac) delivery. MRIdian is the first and only MRI-guided radiation therapy system to receive Shonin approval in Japan, the world's third largest market for radiation oncology.

  • ViewRay Finalizes Order for MR Image-Guided Radiation Therapy System at University Hospital Zurich
    PR Newswirelast month

    ViewRay Finalizes Order for MR Image-Guided Radiation Therapy System at University Hospital Zurich

    CLEVELAND, March 14, 2018 /PRNewswire/ -- ViewRay, Inc. (VRAY) announced today an order for the company's MRIdian® MR image-guided linac at the University Hospital Zurich (USZ) in Zurich, Switzerland. The order formalizes the previously announced tender award from the Swiss National R'Equip programme. Once commissioned, the USZ MRIdian system will be the first in Switzerland, and among the first MR-guided linac systems in Europe to treat patients.

  • Thomson Reuters StreetEventslast month

    Edited Transcript of VRAY earnings conference call or presentation 12-Mar-18 12:30pm GMT

    Q4 2017 ViewRay Inc Earnings Call

  • What Is ViewRay Inc’s (NASDAQ:VRAY) Share Price Doing?
    Simply Wall St.last month

    What Is ViewRay Inc’s (NASDAQ:VRAY) Share Price Doing?

    ViewRay Inc (NASDAQ:VRAY), a medical equipment company based in United States, received a lot of attention from a substantial price movement on the NasdaqGM in the over the last fewRead More...

  • Associated Presslast month

    ViewRay reports 4Q loss

    The Oakwood Village, Ohio-based company said it had a loss of 38 cents per share. The radiation therapy systems maker posted revenue of $19.9 million in the period, which did not meet Street forecasts. ...

  • PR Newswirelast month

    ViewRay Reports Fourth Quarter and Full Year 2017 Financial Results

    Achieved Record Levels of Revenue, Gross Orders and Backlog for Fourth Quarter and Full Year Introduces 2018 Revenue Guidance of $80 - $90 Million CLEVELAND , March 12, 2018 /PRNewswire/ -- ViewRay, Inc. ...

  • ACCESSWIRElast month

    ViewRay, Inc. to Host Earnings Call

    NEW YORK, NY / ACCESSWIRE / March 12, 2018 / ViewRay, Inc. (NASDAQ: VRAY ) will be discussing their earnings results in their Q4 Earnings Call to be held on March 12, 2018 at 8:30 AM Eastern Time. To listen ...

  • PR Newswire2 months ago

    ViewRay Announces Conference Call and Webcast of Fourth Quarter and Full Year 2017 Financial Results to be Held on March 12, 2018

    CLEVELAND , March 6, 2018 /PRNewswire/ -- ViewRay, Inc. (Nasdaq: VRAY) announced today details relating to the release of its fourth quarter and full year 2017 financial results, which will take place ...

  • PR Newswire2 months ago

    ViewRay® to Participate in Upcoming Conferences

    CLEVELAND , Feb. 27, 2018 /PRNewswire/ -- ViewRay, Inc. (NASDAQ: VRAY) announced today that Chris Raanes , Chief Executive Officer, and Ajay Bansal , Chief Financial Officer, are scheduled to participate ...

  • Reuters2 months ago

    BRIEF-ViewRay Announces $59 Mln Equity Financing

    Feb 26 (Reuters) - ViewRay Inc: * VIEWRAY ANNOUNCES $59 MILLION EQUITY FINANCING * VIEWRAY -ENTERED INTO AGREEMENT TO SELL COMMON STOCK AND WARRANTS TO AFFILIATE OF FOSUN INTERNATIONAL IN DIRECT REGISTERED ...

  • PR Newswire2 months ago

    ViewRay Announces $59 Million Equity Financing

    CLEVELAND, Feb. 26, 2018 /PRNewswire/ -- ViewRay, Inc. (VRAY), makers of the world's first and only clinical MRI-guided radiation therapy system, announced today that it has entered into an agreement to sell its common stock and warrants to an affiliate of Fosun International Limited ("Fosun") in a direct registered offering for aggregate gross proceeds of approximately $59.1 million. ViewRay agreed to sell approximately 7.1 million shares of common stock and warrants to purchase approximately 1.4 million shares of common stock for aggregate gross proceeds of approximately $59.1 million before deducting offering expenses.  The warrants will have a per share exercise price of $8.31 per share, equal to the closing price of the Company's common stock on the NASDAQ Global Market on February 23, 2018.

  • PR Newswire2 months ago

    ViewRay Appoints Scott Huennekens and Daniel Moore to its Board of Directors

    CLEVELAND, Feb. 7, 2018 /PRNewswire/ -- ViewRay, Inc. (VRAY), maker of the world's first and only clinical MRI-guided radiation therapy system, announced today the appointment of medical device industry veterans Scott Huennekens and Daniel Moore to the Company's board of directors, effective immediately. Mr. Moore currently serves as chairman of the board for LivaNova PLC, having previously served as chief executive officer of Cyberonics, Inc. prior to its merger with Sorin S.p.A. in 2015 to create LivaNova.

  • Zacks Small Cap Research3 months ago

    VRAY: 2017 Financial Highlights. What To Expect In 2018

    By Anita Dushyanth, PhD NASDAQ:VRAY On January 8, 2018 VRAY (NASDAQ:VRAY) announced preliminary financial results for Q4 and fiscal year 2017. Management had guided for 2017 revenues in the $42 - $47 million ...

  • PR Newswire3 months ago

    ViewRay Announces Preliminary Fourth Quarter and Fiscal Year 2017 Results

    CLEVELAND, Jan. 8, 2018 /PRNewswire/ -- ViewRay, Inc. (VRAY) today announced preliminary results for the fourth quarter and full fiscal year ended December 31, 2017. The preliminary results reported have not been audited and are subject to change. Recognized revenue on 4 MRIdian Linac Systems in Q4 2017.

  • PR Newswire4 months ago

    Oncology Experts to Convene for Symposium to Advance MR Image-Guided Radiation Therapy

    CLEVELAND, Dec. 19, 2017 /PRNewswire/ -- Experts in MR image-guided radiation therapy will share their experiences during a global symposium to be held on Friday, March 16, 2018 in Amsterdam. The event aims to educate clinicians interested in bringing MR image-guided radiation therapy to their institution. The symposium, titled "Advanced Applications of MR-Guided Radiotherapy Symposium," will highlight a full spectrum of MR image-guided radiation therapy topics including underlying technical challenges and system considerations, as well as commissioning and quality assurance protocols.

  • ViewRay Inc (NASDAQ:VRAY): Does 20.2% EPS Decline Lately Make It An Underperformer?
    Simply Wall St.4 months ago

    ViewRay Inc (NASDAQ:VRAY): Does 20.2% EPS Decline Lately Make It An Underperformer?

    Investors with a long-term horizong may find it valuable to assess ViewRay Inc’s (NASDAQ:VRAY) earnings trend over time and against its industry benchmark as opposed to simply looking at aRead More...